Open AccessClinical Outcome and Laboratory Parameters in Sickle Cell Anemia Patients of Pediatric Age Group Post Hydroxyurea Therapy
Author(s) -
Nihar Gupta,
Kishore Hiwale,
Sunita Vagha,
Arvind Bhake,
Sukanya Pawar
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i63a35215
Subject(s) - medicine , sickle cell anemia , anemia , acute chest syndrome , hydroxycarbamide , disease , hemoglobinopathy , pediatrics , hemolytic anemia
Background: Homozygous condition in Sickle cell disease (SCD) is called as sickle cell anemia(SCA). In sickle cell anemia patients clinically presents as hemolytic anemia, vaso-occlusive events, along with organ dysfunction and acute chest syndrome. Recently Hydroxyurea has shown promising results in treatment of sickle cell anemia. Hydroxyurea is the only approved drug by FDA which has shown disease modifying results.
Aim: To determine the clinical outcome and laboratory parameters in SCA patients of pediatric age group post-hydroxyurea therapy.
Methods: A total of 30 patients who were diagnosed as Sickle cell anemia (SCA) patients in Sickle cell anemia OPD of Pediatric department were included in the study.
Results: Hydroxyurea therapy is expected to increase HbF% levels and improve the clinical outcome and laboratory parameters in sickle cell anemia patients of pediatric age group.